Genomic Testing: A Game Changer in Breast Cancer Survival Disparities

New research highlights the impact of advanced genomic testing on reducing breast cancer survival disparities between Black and white women. By utilizing advanced gene-profiling tools, researchers found that genomic testing classified tumors more accurately, leading to improved treatment outcomes for Black women, matching those of white women once appropriate care was provided.

Advanced genomic testing has been identified as a potential equalizer in erasing disparities in breast cancer survival rates between Black and white patients, according to recent research. Despite Black women in the U.S. having a 40% higher breast cancer mortality rate than white women, the application of genomic testing revealed a path for improved outcomes.

The study, highlighted in npj Breast Cancer, utilized MammaPrint and BluePrint tests from Agendia on tumor samples from more than a thousand women. Results showed that when tumors were analyzed with these gene-profiling tools, and patients received appropriate care, Black women reached survival outcomes equivalent to their white counterparts. Notably, three-year recurrence-free survival was driven by genomic subtype.

Dr. Andrea Menicucci of Agendia emphasized the importance of genomic testing for all patients, indicating that its widespread use may guide better treatment decisions and ultimately reduce racial survival disparities. As this testing becomes more prevalent, it promises to standardize care across racial lines and improve prognoses for all women diagnosed with breast cancer.